August 3, 2016
Teijin has called off the development of TMX-67XR, an extended-release version of its mainstay gout and hyperuricemia treatment Feburic (febuxostat), the company revealed on August 2. TMX-67XR was under PIII development in Japan. The company failed to obtain expected efficacy...read more